SCHEMBL266441

SCHEMBL266441

COc1ccc(C(=O)Nc2cc(Cl)ccc2C(=O)N/N=C/c2cccc(C)c2)cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.59
RAB9A P51151 2/20 0.59
NPC1 O15118 1/20 0.59
KDM4E B2RXH2 4/20 0.56
TDP1 Q9NUW8 2/20 0.56
HTT P42858 2/20 0.56
OPRK1 P41145 1/20 0.56
MAPT P10636 6/20 0.51
ALDH1A1 P00352 2/20 0.51
POLB P06746 2/20 0.51
HSD11B1 P28845 1/20 0.51
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
HPGD P15428 1/20 0.49
ALOX12 P18054 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
GAA P10253 1/20 0.48
PDE4D Q08499 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266442 1.00 PKM (0.59) PKMRAB9ANPC1KDM4ETDP1
SCHEMBL266901 0.93 RAB9A (0.59) PKMRAB9ANPC1KDM4ETDP1
SCHEMBL266900 0.93 RAB9A (0.59) PKMRAB9ANPC1KDM4ETDP1
SCHEMBL265934 0.92 NPC1 (0.62) PKMRAB9ANPC1KDM4ETDP1
SCHEMBL265933 0.92 NPC1 (0.62) PKMRAB9ANPC1KDM4ETDP1
SCHEMBL265355 0.90 RAB9A (0.58) PKMRAB9ANPC1KDM4ETDP1
SCHEMBL265354 0.90 RAB9A (0.58) PKMRAB9ANPC1KDM4ETDP1
SCHEMBL265901 0.90 PKM (0.62) PKMRAB9ANPC1KDM4ETDP1
SCHEMBL265900 0.90 PKM (0.62) PKMRAB9ANPC1KDM4ETDP1
SCHEMBL268131 0.89 NPC1 (0.74) PKMRAB9ANPC1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 PKM 1697/4885RAB9A 883/4885NPC1 102/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 PKM 1916/4885RAB9A 1362/4885NPC1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.